IOL CHEM AND PHARMA LTD

IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced three strategic growth initiatives during its September 11, 2026, business update call, involving a proposed investment of approximately INR500 crores. These initiatives include expanding Ibuprofen capacity by 6,000 MTPA to a total of 18,000 MTPA, establishing a CDMO facility with a capacity of 1,500 million tablets per annum, and setting up a specialty chemical facility under a long-term tolling arrangement with a global chemical company. Management expects the Ibuprofen expansion to be commissioned by December 2027, with optimal utilization anticipated in 2028-2029. Management expects the CDMO facility, which received EU GMP certification, to commercialize in Q3 FY27, with revenue projections of 1.75x to 2x the investment at peak utilization. The specialty chemical facility is customer-led, providing long-term manufacturing demand visibility. Management emphasized that these projects are part of a long-term strategy to strengthen core businesses, diversify, and deepen customer relationships. The investments are planned to be funded through internal accruals, with 30% of the total funding already incurred. Management noted that these initiatives are expected to contribute an incremental 25% to 30% to the top line over the coming years. Management also discussed the impact of these projects on EBIT and cash flow, stating that the capex would be funded internally and would not significantly impact EBIT in the near term. The company highlighted its backward integration in Ibuprofen and Paracetamol, which helps manage raw material price fluctuations, and noted that the CDMO business is expected to have higher margins compared to API segments. The call concluded with management reiterating the company's focus on disciplined execution and long-term value creation for stakeholders.

The document emphasizes strategic growth initiatives, long-term confidence, and positive revenue projections, indicating a positive tone.